

02-23-2004



102674734

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks

Send original documents or copy thereof.

1. Name of conveying party(ies):

Stratagene California, formerly known as
StratageneAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☐ Assignment ☐ Merger
☒ Security Agreement ☐ Change of Name
☐ Other _____

Execution Date: 02/03/2004

2. Name and address of receiving party(ies):

Name: TCW Special Credits Fund V - The

Internal Address: Principal Fund

c/o Oaktree Capital Management, LLC

Street Address: 333 South Grand Avenue
Suite 2800

City: Los Angeles State: CA Zip: 90071

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s) _____

B. Patent No.(s) See attached list

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Michael G. Fatall, Esq.

Internal Address: Kirkland & Ellis LLP

Suite 5300

Street Address: 200 East Randolph Drive

City: Chicago State: IL Zip: 60601

6. Total number of applications and patents involved: 23

7. Total fee (37 CFR 3.41).....\$ 920

- ☐ Enclosed
☒ Authorized to be charged to deposit account

8. Deposit account number:

22-0440

DO NOT USE THIS SPACE

9. Signature.

Michael G. Fatall

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachments, and documents: 16

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

U.S. Patent No.	Title	Issue Date
6657169	Apparatus for thermally cycling samples of biological material with substantial temperature uniformity	December 2, 2003
6391548	Circular site-directed mutagenesis	May 21, 2002
5789166	Circular site-directed mutagenesis	August 4, 1998
5932419	Circular site-directed mutagenesis	August 3, 1999
6489150	Purified thermostable Pyrococcus furiosus DNA polymerase I	December 3, 2002
6444428	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	September 3, 2002
6379553	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	April 30, 2002
6333165	Methods for identifying polymerase enhancing factor (PEF)	December 25, 2001
6183997	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	February 6, 2001
5948663	Purified thermostable pyrococcus furiosus DNA polymerase I	September 7, 1999
5866395	Purified thermostable pyrococcus furiosus DNA polymerase I	February 2, 1999
5556772	Polymerase compositions and uses thereof	September 17, 1996
5545552	Purified thermostable pyrococcus furiosus DNA polymerase I	August 13, 1996
5512468	Process of producing highly transformable bacterial cells and cells produced thereby	April 30, 1996
5707841	Process of producing highly transformable bacterial cells and cells produced thereby	January 13, 1998

U.S. Patent No.	Title	Issue Date
6338965	Method for more efficient electroporation	January 15, 2002
6040184	Method for more efficient electroporation	March 21, 2000
6054263	Thermal cycler including a temperature gradient block	April 25, 2000
5525300	Thermal cycler including a temperature gradient block	June 11, 1996
6017748	Cloning host organisms	January 25, 2000
5779981	Thermal cycler including a temperature gradient block	July 14, 1998
5552314	Cloning host organisms	September 3, 1996
5128256	DNA cloning vectors with in vivo excisable plasmids	July 7, 1992

02/09/2004
700064926

Form PTO-100 (Rev. 10/02) OMB No. 0651-0047 (exp. 6/30/2006) The fee is \$100.		RECORDATION FORM COVER SHEET PATENTS ONLY		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): Stratagene California, formerly known as Stratagene		2. Name and address of receiving party(ies): Name: <u>ICM Special Credits Fund - The Principal Fund</u> Internal Address: <u>c/o Oaktree Capital Management, LLC</u> Street Address: <u>333 South Grand Avenue</u> <u>Suite 2800</u> City: <u>Los Angeles</u> State: <u>CA</u> Zip: <u>90071</u>			
Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No		Additional name(s) & addresses attached? ☐ Yes ☒ No			
3. Nature of conveyance: ☐ Assignment ☐ Merger ☒ Security Agreement ☐ Change of Name ☐ Other _____		Execution Date: <u>02/03/2004</u>			
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) _____ B. Patent No.(s) _____ see attached list Additional numbers attached? ☒ Yes ☐ No		5. Total number of applications and patents involved: <u>23</u>			
6. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Michael C. Farrell, Esq.</u> Internal Address: <u>Kirkland & Ellis LLP</u> <u>Suite 5300</u> Street Address: <u>200 East Randolph Drive</u> City: <u>Chicago</u> State: <u>IL</u> Zip: <u>60601</u>		7. Total fee (\$7 CFR 5.41)..... <u>\$920</u> ☐ Enclosed ☒ Authorized to be charged to deposit account <u>22-0440</u>			
		8. Deposit account number: <u>22-0440</u> (Attach duplicate copy of this page if paying by deposit account)			
DO NOT USE THIS SPACE					
9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. <u>Michael C. Farrell</u> Name of Person Signing  Signature <u>2/6/04</u> Date					
Total number of pages including cover sheet, attachments, and documents: <u>5</u>					

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, USPTO
Washington, D.C. 20541

U.S. Patent No.	Title	Issue Date
6457163	Apparatus for thermally cycling samples of biological material with submicronial temperature uniformity	December 2, 2003
6591548	Circular site-directed mutagenesis	May 21, 2002
5769166	Circular site-directed mutagenesis	August 4, 1998
5932419	Circular site-directed mutagenesis	August 3, 1998
6489150	Purified thermostable pyrococcus furiosus DNA polymerase I	December 3, 1999
6444128	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	September 3, 2002
6379553	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	April 30, 2002
6333166	Methods for identifying polymerase enhancing factor (PEF)	December 25, 2001
6162997	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	February 5, 2001
5948605	Purified thermostable pyrococcus furiosus DNA polymerase I	September 7, 1999
5166595	Purified thermostable pyrococcus furiosus DNA polymerase I	February 4, 1998
5358772	Polymerase compositions and uses thereof	September 17, 1996
5343553	Purified thermostable pyrococcus furiosus DNA polymerase I	August 15, 1996
5313448	Process of producing highly transformable bacterial cells and cells produced thereby	April 30, 1996
5707841	Process of producing highly transformable bacterial cells and cells produced thereby	January 13, 1998
6336963	Method for using purified electroporators	January 13, 2002
6040184	Method for more efficient electroporation	March 21, 2000
6054263	Thermal cycles including a temperature gradient block	April 25, 2000
5325000	Thermal cycles including a temperature gradient block	June 11, 1996
6017748	Cloning host organisms	January 24, 2000
5776081	Thermal cycles including a temperature gradient block	July 14, 1998
5552114	Cloning host organisms	September 3, 1996
5128236	DNA cloning vectors with in vivo nucleable plasmids	July 7, 1992

02/04/2004 12:12 FAX 3123541948

OAKTREE CAPITAL MGR.

0002/000

PATENT SECURITY AGREEMENT

PATENT SECURITY AGREEMENT dated February 9, 2004 made by Strategene California, a California corporation formerly known as Strategene, having its principal place of business at 11011 North Torrey Pines Road, La Jolla, California 92037 (the "Grantor"), in favor of TCW Special Credits Fund V - The Principal Fund, a California limited partnership, as agent, having its principal place of business at c/o Oaktree Capital Management, LLC, 333 South Grand Avenue, Suite 2800, Los Angeles, California 90071 (the "Grantee"), for the ratable benefit of the Secured Party (as defined in the Security Agreement).

The Grantor and the Grantee entered into a Security Agreement dated January 21, 2004 (as amended, supplemented or otherwise modified hereafter from time to time, the "Security Agreement") with the other grantors party thereto, pursuant to which the Grantor has granted to the Grantee (for the ratable benefit of the Secured Party) a first and security interest in, inter alia, all of the Grantor's rights, title, and interest in and to all Patents (as defined in the Security Agreement) of such Grantor whether then owned or thereafter acquired or created by such Grantor, including, without limitation, the patents listed on Schedule A hereto (the "Patent Collateral").

The parties desire to record the Grantor's grant of the security interest in the Patent Collateral to the Grantee with the United States Patent & Trademark Office.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby agrees with the Grantee (for the ratable benefit of the Secured Party) as follows:

1. The Security Agreement and its terms and provisions are incorporated herein in their entirety.
2. The Grantor grants to the Grantee a security interest in all of its right, title, and interest in and to the Patent Collateral.

000010047

IN WITNESS WHEREOF, the Ombudsman has caused this Public Security Agreement to be duly executed and delivered by its officer thereunto duly authorized, as of the date first written above.

STRATAGENE CALIFORNIA

By: Ronald L. Smith
Name: Ronald L. Smith
Title: EXECUTIVE VICE PRESIDENT AND
GENERAL COUNSEL

Authorized and Accepted:

TCW Special Credit Fund V - The Principal Fund

By: William F. Smith
Name: William F. Smith
Title: Authorized Signatory on behalf of
TCW Asset Management Company,
The General Partner

02/04/2004 12:13 FAX 3123441049

DAVIDSON CAPITAL INC.

SCHEDULE A

PATENT SCHEDULE

Patent No.	Title	Issue Date
6,657,169	Apparatus for thermally cycling samples of biological material with substantial temperature uniformity	December 2, 2003
6,391,548	Circular site-directed mutagenesis	May 21, 2002
5,789,166	Circular site-directed mutagenesis	August 4, 1998
5,932,419	Circular site-directed mutagenesis	August 3, 1999
6,489,150	Purified thermostable <i>Pyrococcus furiosus</i> DNA polymerase I	December 3, 2002
6,444,428	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	September 3, 2002
6,379,553	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	April 30, 2002
6,333,165	Methods for identifying polymerase enhancing factor (PEF)	December 25, 2001
6,183,997	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	February 6, 2001
5,348,683	Purified thermostable <i>pyrococcus furiosus</i> DNA polymerase I	September 7, 1999
5,866,305	Purified thermostable <i>pyrococcus furiosus</i> DNA polymerase I	February 2, 1999
5,336,772	Polymerase compositions and uses thereof	September 17, 1996
5,543,552	Purified thermostable <i>pyrococcus furiosus</i> DNA polymerase I	August 13, 1996

02/04/2004 12:18 FAX 3128811949

CANTREX CAPITAL BOX.

02065/006

Paper No.	Title	Issue Date
5,512,468	Process of producing highly transformable bacterial cells and cells produced thereby	April 30, 1995
5,707,841	Process of producing highly transformable bacterial cells and cells produced thereby	January 15, 1998
6,338,965	Method for more efficient electroporation	January 15, 2002
6,040,184	Method for more efficient electroporation	March 21, 2000
6,054,263	Thermal cycler including a temperature gradient block	April 25, 2000
5,525,300	Thermal cycler including a temperature gradient block	June 11, 1996
6,017,748	Cloning host organisms	January 25, 2000
5,779,981	Thermal cycler including a temperature gradient block	July 14, 1998
5,552,514	Cloning host organisms	September 3, 1996
5,138,256	DNA cloning vectors with in vivo excisable plasmids	July 7, 1992

02065/006

KIRKLAND & ELLIS
Fax Transmittal

200 East Randolph Drive
Chicago, Illinois 60601
Phone: (312) 881-2200
Fax: (312) 881-2200

Please notify us immediately if any pages are not received

THE INFORMATION CONTAINED IN THIS COMMUNICATION IS CONFIDENTIAL, MAY BE ATTORNEY-CLIENT PRIVILEGED, MAY CONSTITUTE INSIDE INFORMATION, AND IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE. UNAUTHORIZED USE, DISCLOSURE OR COPYING IS STRICTLY PROHIBITED AND MAY BE UNLAWFUL.

PATENT
REEL: 014981 FRAME: 0668

PATENT SECURITY AGREEMENT

PATENT SECURITY AGREEMENT dated February 3, 2004 made by Stratagene California, a California corporation formerly known as Stratagene, having its principal place of business at 11011 North Torrey Pines Road, La Jolla, California 92037 (the "*Grantor*"), in favor of TCW Special Credits Fund V – The Principal Fund, a California limited partnership, as agent, having its principal place of business at c/o Oaktree Capital Management, LLC, 333 South Grand Avenue, Suite 2800, Los Angeles, California 90071 (the "*Grantee*"), for the ratable benefit of the Secured Party (as defined in the Security Agreement).

The Grantor and the Grantee entered into a Security Agreement dated January 21, 2004 (as amended, supplemented or otherwise modified hereafter from time to time, the "*Security Agreement*") with the other grantors party thereto, pursuant to which the Grantor has granted to the Grantee (for the ratable benefit of the Secured Party) a lien on and security interest in, inter alia, all of the Grantor's rights, title, and interest in and to all Patents (as defined in the Security Agreement) of such Grantor whether then owned or thereafter acquired or created by such Grantor, including, without limitation, the patents listed on Schedule A hereto (the "*Patent Collateral*").

The parties desire to record the Grantor's grant of the security interest in the Patent Collateral to the Grantee with the United States Patent & Trademark Office.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby agrees with the Grantee (for the ratable benefit of the Secured Party) as follows:

1. The Security Agreement and its terms and provisions are incorporated herein in their entirety.
2. The Grantor grants to the Grantee a security interest in all of its right, title, and interest in and to the Patent Collateral.

NSDA310042

FEB-03-04 11:16AM FROM-

T-007 P.003/005 F-780

IN WITNESS WHEREOF, the Grantor has caused this Patent Security Agreement to be duly executed and delivered by its officer thereunto duly authorized, as of the date first written above.

STRATAGENE CALIFORNIA

By: Ronni L. Sherman
Name: RONNI L. SHERMAN
Title: EXECUTIVE VICE PRESIDENT AND
GENERAL COUNSEL

Acknowledged and Accepted:

TCW Special Credits Fund V - The Principal Fund

By: Vincent J. Cabala
Name: Vincent J. Cabala
Title: Authorized Signatory on behalf of
TCW Asset Management Company,
Its General Partner

SCHEDULE A

PATENT SCHEDULE

Patent No.	Title	Issue Date
6,657,169	Apparatus for thermally cycling samples of biological material with substantial temperature uniformity	December 2, 2003
6,391,548	Circular site-directed mutagenesis	May 21, 2002
5,789,166	Circular site-directed mutagenesis	August 4, 1998
5,932,419	Circular site-directed mutagenesis	August 3, 1999
6,489,150	Purified thermostable Pyrococcus furiosus DNA polymerase I	December 3, 2002
6,444,428	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	September 3, 2002
6,379,553	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	April 30, 2002
6,333,165	Methods for identifying polymerase enhancing factor (PEF)	December 25, 2001
6,183,997	Polymerase enhancing factor (PEF) extracts, PEF protein complexes, isolated PEF proteins, and methods for purifying and identifying same	February 6, 2001
5,948,663	Purified thermostable pyrococcus furiosus DNA polymerase I	September 7, 1999
5,866,395	Purified thermostable pyrococcus furiosus DNA polymerase I	February 2, 1999
5,556,772	Polymerase compositions and uses thereof	September 17, 1996
5,545,552	Purified thermostable pyrococcus furiosus DNA polymerase I	August 13, 1996

Patent No.	Title	Issue Date
5,512,468	Process of producing highly transformable bacterial cells and cells produced thereby	April 30, 1996
5,707,841	Process of producing highly transformable bacterial cells and cells produced thereby	January 13, 1998
6,338,965	Method for more efficient electroporation	January 15, 2002
6,040,184	Method for more efficient electroporation	March 21, 2000
6,054,263	Thermal cycler including a temperature gradient block	April 25, 2000
5,525,300	Thermal cycler including a temperature gradient block	June 11, 1996
6,017,748	Cloning host organisms	January 25, 2000
5,779,981	Thermal cycler including a temperature gradient block	July 14, 1998
5,552,314	Cloning host organisms	September 3, 1996
5,128,256	DNA cloning vectors with in vivo excisable plasmids	July 7, 1992